FBRX: Chardan Capital Maintains Buy Rating, $61 Target Unchanged

Chardan Capital has maintained its "Buy" rating for Forte Biosciences (FBRX) with a price target of $61. The rating reflects the analyst's confidence in the stock's performance. The average target price from 3 analysts is $45.67, with a high estimate of $61 and a low of $19. The average target implies an upside of 322.06% from the current price of $10.82.

Forte Biosciences (FBRX) is set to release its Q2 2025 earnings results on August 13, with analysts expecting a loss of ($1.21) per share. The company's latest earnings report showed a loss of ($1.37) per share, significantly below the consensus estimate of ($0.89) [1].

Analysts' opinions are mixed. Chardan Capital maintains a "buy" rating with a price target of $61, while Wall Street Zen downgraded their rating from "hold" to "sell" [1]. The average target price from 3 analysts is $45.67, with a high estimate of $61 and a low of $19, implying an average upside of 322.06% from the current price of $10.82 [2].

Forte Biosciences, a biopharmaceutical company based in Dallas, Texas, operates in the autoimmune disease treatment space. The company's lead product, FB-102, is in clinical trials for conditions like graft-versus-host disease, vitiligo, and alopecia areata. The company reported a GAAP net loss per share of $(0.96) for Q2 2025, beating analyst estimates of $(1.11) [2].

The company's financial position is fortified with $106.1 million in cash and cash equivalents as of June 30, 2025, following a June capital raise. Research and development expenses (GAAP) rose 50.9% to $8.6 million, while general and administrative expenses dropped to $3.0 million [2].

Forte Biosciences expects 2026 to bring major inflection points as it discloses key safety and preliminary efficacy data for FB-102 across celiac disease, vitiligo, and alopecia areata. The company does not currently pay a dividend and investors should watch for clinical trial enrollment, data releases in 2026, and the sustainability of its cash resources.

References:
[1] https://www.marketbeat.com/instant-alerts/forte-biosciences-fbrx-to-release-earnings-on-wednesday-2025-08-06/
[2] https://www.nasdaq.com/articles/forte-biosciences-tops-q2-loss-forecasts